Pan-European French listed nursing home group Clariane has sold nine nursing home properties to Belgian real estate investor Care Property Invest. Clariane will continue operating the homes.
US healthcare conglomerate UnitedHealth has exited Latin America with the sale of its last subsidiary in the region, hospital chain Empresas Banmedica, to Latino private equity firm Patria Investments.
Private markets and real estate investment firm Reuben Brothers has increased its hold on UK nursing home group Avery Healthcare, indicating US REIT Welltower has reduced, or perhaps completely sold, its stake.
The UK Chancellor, Rachel Reeves, delivered her second Budget on November 26. One of the big health-related announcements was that the government plans to open up to 250 ‘Neighbourhood Health Centres’ across England, with 120 of these expected to be ready by 2030.
Vitabiotics, the UK’s largest nutraceutical company specialising in vitamin and mineral-based supplements, is up for sale and has attracted interest from several potential buyers, including Swedish investment firm EQT, American private equity firm TPG, and Indian pharmaceutical company Lupin.
The deal could value Vitabiotics at around £1 billion ($1.32 billion), a 14x multiple of the company’s 2024 EBITDA.
The private equity sector has faced a difficult environment for dealmaking over the past two and a half years, due to higher interest rates, regulatory uncertainty and global political pressures. This has led to a slowdown in M&A deal activity in healthcare, as well as other sectors. There are now signs of recovery. Europe is attracting more interest from global investors, especially those seeking high-quality assets with strong growth potential.
Pan-European French nursing home group Colisée has become so overburdened by its debt that its creditors have insisted on taking control from private equity firm EQT, who has owned it since 2020.
Private equity firm CapVest will continue to be the majority shareholder of Curium Pharma, the world’s largest pure play nuclear medicine producer, for another three-to-five-year investment round. The company is being moved to a continuation vehicle in a recapitalisation deal that values it at around $7 billion.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.
